BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 18414863)

  • 21. Comparison of cytogenetics with FISH in 40 myelodysplastic syndrome patients.
    Romeo M; Chauffaille Mde L; Silva MR; Bahia DM; Kerbauy J
    Leuk Res; 2002 Nov; 26(11):993-6. PubMed ID: 12363467
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Myelodysplastic syndromes (MDS)].
    Germing U; Kündgen A; Haas R; Gattermann N
    Dtsch Med Wochenschr; 2012 Feb; 137(5):183-5. PubMed ID: 22278686
    [No Abstract]   [Full Text] [Related]  

  • 23. Conventional and molecular cytogenetic features of myelodysplastic syndrome in China.
    Chen L; Li J; Zhu Y; Qiu H; Pan J; Wang R; Qian S; Xu W; Xue Y
    Exp Oncol; 2007 Dec; 29(4):299-303. PubMed ID: 18199987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapy-related myelodysplastic syndrome after eradication of acute promyelocytic leukemia: cytogenetic and molecular features.
    Au WY; Lam CC; Ma ES; Man C; Wan T; Kwong YL
    Hum Pathol; 2001 Jan; 32(1):126-9. PubMed ID: 11172306
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide.
    Sugimoto Y; Sekeres MA; Makishima H; Traina F; Visconte V; Jankowska A; Jerez A; Szpurka H; O'Keefe CL; Guinta K; Afable M; Tiu R; McGraw KL; List AF; Maciejewski J
    J Hematol Oncol; 2012 Mar; 5():4. PubMed ID: 22390313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.
    Haase D; Stevenson KE; Neuberg D; Maciejewski JP; Nazha A; Sekeres MA; Ebert BL; Garcia-Manero G; Haferlach C; Haferlach T; Kern W; Ogawa S; Nagata Y; Yoshida K; Graubert TA; Walter MJ; List AF; Komrokji RS; Padron E; Sallman D; Papaemmanuil E; Campbell PJ; Savona MR; Seegmiller A; Adès L; Fenaux P; Shih LY; Bowen D; Groves MJ; Tauro S; Fontenay M; Kosmider O; Bar-Natan M; Steensma D; Stone R; Heuser M; Thol F; Cazzola M; Malcovati L; Karsan A; Ganster C; Hellström-Lindberg E; Boultwood J; Pellagatti A; Santini V; Quek L; Vyas P; Tüchler H; Greenberg PL; Bejar R;
    Leukemia; 2019 Jul; 33(7):1747-1758. PubMed ID: 30635634
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytogenetic and Southern blot analysis to demonstrate clonality and to estimate prognosis in patients with myelodysplastic syndromes.
    Schmetzer HM; Poleck B; Duell T; Gerhartz HH; Mittermüller J
    Ann Hematol; 2000 Jan; 79(1):20-9. PubMed ID: 10663617
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Childhood myelodysplastic syndrome.
    Chatterjee T; Choudhry VP
    Indian J Pediatr; 2013 Sep; 80(9):764-71. PubMed ID: 23912822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytogenetic analysis in patients with myelodysplastic syndrome.
    Hu N; Bian M
    Proc Chin Acad Med Sci Peking Union Med Coll; 1990; 5(3):135-9. PubMed ID: 2098765
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Diagnosis and prognosis in myelodysplastic syndromes. The impact of cytogenetics].
    Mecucci C
    Recenti Prog Med; 2014 Mar; 105(3):110-4. PubMed ID: 24675452
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interphase FISH does not improve the detection of DEL(5q) and DEL(20q) in myelodysplastic syndromes.
    Douet-Guilbert N; Herry A; LE Bris MJ; Guéganic N; Bovo C; Morel F; DE Braekeleer M
    Anticancer Res; 2011 Mar; 31(3):1007-10. PubMed ID: 21498729
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia.
    Maciejewski JP; Risitano A; Sloand EM; Nunez O; Young NS
    Blood; 2002 May; 99(9):3129-35. PubMed ID: 11964274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic and prognostic significance of cytogenetics in adult primary myelodysplastic syndromes.
    Jotterand M; Parlier V
    Leuk Lymphoma; 1996 Oct; 23(3-4):253-66. PubMed ID: 9031106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiplex ligation-dependent probe amplification assay identifies additional copy number changes compared with R-band karyotype and provide more accuracy prognostic information in myelodysplastic syndromes.
    Wang J; Ai X; Qin T; Xu Z; Zhang Y; Liu J; Li B; Fang L; Zhang H; Pan L; Hu N; Qu S; Cai W; Ru K; Jia Y; Huang G; Xiao Z
    Oncotarget; 2017 Jan; 8(1):1603-1612. PubMed ID: 27906673
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conventional and molecular cytogenetic findings of myelodysplastic syndrome patients.
    Yilmaz Z; Sahin FI; Kizilkilic E; Karakus S; Boga C; Ozdogu H
    Clin Exp Med; 2005 Jul; 5(2):55-9. PubMed ID: 16096854
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A prognostic impact of separation of refractory cytopenia with multilineage dysplasia and 5q- syndrome from refractory anemia in primary myelodysplastic syndrome.
    Cermák J; Michalová K; Brezinová J; Zemanová Z
    Leuk Res; 2003 Mar; 27(3):221-9. PubMed ID: 12537974
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A new recurrent translocation, t(5;11)(q35;p15.5), associated with del(5q) in childhood acute myeloid leukemia. The UK Cancer Cytogenetics Group (UKCCG).
    Jaju RJ; Haas OA; Neat M; Harbott J; Saha V; Boultwood J; Brown JM; Pirc-Danoewinata H; Krings BW; Müller U; Morris SW; Wainscoat JS; Kearney L
    Blood; 1999 Jul; 94(2):773-80. PubMed ID: 10397745
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis.
    Kulasekararaj AG; Smith AE; Mian SA; Mohamedali AM; Krishnamurthy P; Lea NC; Gäken J; Pennaneach C; Ireland R; Czepulkowski B; Pomplun S; Marsh JC; Mufti GJ
    Br J Haematol; 2013 Mar; 160(5):660-72. PubMed ID: 23297687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytogenetic features of 5q deletion and 5q- syndrome in myelodysplastic syndrome in Korea; marker chromosomes proved to be chromosome 5 with interstitial deletion by fluorescence in situ hybridization.
    Lee HR; Oh B; Hong DS; Zang DY; Yoon HJ; Kim HJ; Kim I; Ahn JS; Cheong JW; Lee KA; Cho KS; Lee MH; Bang SM; Kim TY; Yun YM; Min YH; Lee YK; Lee DS;
    Cancer Genet Cytogenet; 2010 Dec; 203(2):193-202. PubMed ID: 21156233
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chromosomal aberrations in bone marrow mesenchymal stroma cells from patients with myelodysplastic syndrome and acute myeloblastic leukemia.
    Blau O; Hofmann WK; Baldus CD; Thiel G; Serbent V; Schümann E; Thiel E; Blau IW
    Exp Hematol; 2007 Feb; 35(2):221-9. PubMed ID: 17258071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.